Table 1.
Baseline Characteristics
| Characteristic | Total (N=25) |
|---|---|
| Median age (range) | 62 (35–84) |
| Men | 9 (36%) |
| Women | 16 (64%) |
| Karnofsky performance status | |
| ≥90% | 5 (20%) |
| 80% | 9 (36%) |
| 70% | 7 (28%) |
| 60% | 4 (16%) |
| Stage at diagnosis (%) | |
| Limited | 7 (28%) |
| Extensive | 18 (72%) |
| Sensitive | 16 (64%) |
| Refractory | 9 (36%) |
| Previous lines of therapy | |
| Onea | 15 (60%) |
| Twob | 10 (40%) |
| Brain metastases | 10 (40%) |
a
First-line treatment was a platinum/etoposide doublet except for 3 patients: 1 received platinum/etoposide with irinotecan, 1 received platinum and irinotecan, and 1 received platinum/etoposide and IMC-A12.
b
Second-line treatments included rechallenge with platinum/etoposide (N=3), cyclophosphamide/doxorubicin/vincristine (N=3), topotecan (N=2), taxanes (N=1), and platinum with irinotecan (N=1).